

PARTICIPATING FACULTY

Emerging Trends and Formulary Considerations for Atypical Antipsychotics

This supplement to *The American Journal of Managed Care* contains information on atypical antipsychotics and their cost effectiveness in the treatment of schizophrenia and bipolar disease.

Faculty

David J. Harrison, PhD

Senior Manager
US Outcomes Research
Pfizer Inc
New York, NY

Robin P. Hertz, PhD

Senior Director
Pfizer Inc
New York, NY

Amie T. Joyce, MPH

Senior Research Consultant
PharMetrics, Inc
Watertown, MA

Antony D. Loebel, MD

Medical Director
Pfizer Inc
New York, NY

Michael B. Lustik, MS

Statistician
Science Applications International
Corporation
Reston, VA

Margaret McDonald, PhD

Director
Pfizer Inc
New York, NY

Daniel A. Ollendorf, MPH

Vice President
Analytic & Consulting Services
PharMetrics, Inc
Watertown, MA

George M. Simpson, MD

Professor of Research in Psychiatry
Department of Psychiatry and
the Behavioral Sciences
LAC + USC Medical Center
Los Angeles, CA

Richard C. Surles, PhD

Senior Vice President and Director
Comprehensive NeuroScience, Inc
White Plains, NY

Alan N. Unger, PhD

Senior Statistician
Science Applications International
Corporation
Reston, VA

Disclosure Statement

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following participants have declared the following affiliations with corporate organizations:

■ **David J. Harrison, PhD**

Employee:
Pfizer Inc

■ **Robin P. Hertz, PhD**

Employee:
Pfizer Inc

■ **Amie T. Joyce, MPH**

Research Support:
Pfizer Inc

■ **Antony D. Loebel, MD**

Employee:
Pfizer Inc

■ **Michael B. Lustik, MS**

Contractor:
Pfizer Inc

■ **Margaret McDonald, PhD**

Employee:
Pfizer Inc

■ **Daniel A. Ollendorf, MPH**

Research Support:
Pfizer Inc

■ **George M. Simpson, MD**

Consultant:
Janssen
Pfizer

Research Support:
AstraZeneca
GlaxoSmithKline
Janssen
Pfizer

■ **Richard C. Surles, PhD**

Adviser:
Eli Lilly and Company

■ **Alan N. Unger, PhD**

Contractor:
Pfizer Inc

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

*Emerging Trends and Formulary Considerations
for Atypical Antipsychotics*

This supplement was funded by **Pfizer Inc.**

Acknowledgments

We would like to thank Laura Brasseur and Debbie Godfrey for their contributions to this supplement.

• • •

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.